
Abstract: Depression remains a leading cause of morbidity worldwide, with conventional monoaminergic antidepressants such as SSRIs and SNRIs limited by delayed onset and high rates of treatment resistance. Novel approaches that modulate neuroplasticity, particularly NMDA receptor antagonists like ketamine, have demonstrated rapid efficacy in treatment-resistant depression. Ketamine relieves symptoms within hours by promoting glutamate release, AMPA receptor activation, BDNF–TrkB signaling, and mTOR pathway engagement, leading to synaptic remodeling. This review focuses on ketamine as an adjunct or alternative to monoaminergic therapies, highlighting mechanistic pathways of synaptic scaling and dendritic spine formation. Comparative insights into psychedelics, neurosteroids, and investigational NMDA modulators are also discussed, with emphasis on translational limitations, biomarker feasibility, and ethical challenges in digital therapeutics.
Introduction: Stress-related disorders have become a major global health concern, contributing substantially to psychological, metabolic, and neurodegenerative conditions. Adaptogenic herbs, traditionally used in Ayurvedic, Chinese, Korean, and Indigenous medical systems, have gained scientific interest because of their potential to enhance stress resilience, normalize physiological functions, and modulate neuroendocrine responses. These botanicals exert multitarget effects, including regulation of the hypothalamic–pituitary–adrenal (HPA) axis, antioxidant activity, and modulation of key neurotransmitters. A growing body of evidence highlights the potential of adaptogens such as Withania somnifera, Rhodiola rosea, Panax ginseng, Bacopa monnieri, and others to alleviate psychological stress, enhance cognitive performance, and support metabolic balance. Methods: Major adaptogenic herbs were evaluated by examining preclinical, molecular, and clinical literature related to stress physiology. Relevant databases were searched for studies reporting effects on glucocorticoids, HPA-axis biomarkers, oxidative stress pathways, neurotransmitter balance, immune modulation, and subjective psychological stress outcomes. Historical and ethnomedicinal sources were also reviewed to contextualize traditional uses. Results: Evidence indicates that adaptogens may regulate the HPA axis by modulating CRH, ACTH, and cortisol levels; enhance cellular protection by inducing heat shock protein 70 (Hsp70); and activate antioxidant pathways, including the Nrf2 pathway. Several adaptogenic herbs exhibit anxiolyticand antidepressant-like effects through modulation of GABA, serotonin, and dopamine signaling. They may also reduce inflammatory markers, improve mitochondrial energy metabolism, and mitigate cognitive fatigue. Clinical findings suggest potential improvements in mild-to-moderate anxiety, perceived stress, cognitive performance, and fatigue, although the strength of evidence varies among individual adaptogens and study designs. Discussion: Adaptogens differ from conventional anxiolytics and antidepressants in that they are proposed to exert broad, systems-level regulatory effects rather than acting primarily on a single pharmacological target. Their pleiotropic neuroendocrine, antioxidant, immunomodulatory, and cytoprotective actions may support their therapeutic potential in chronic stress and related conditions. However, direct comparisons with established pharmacotherapies remain limited, and claims regarding dependence, withdrawal, and comparative safety require cautious interpretation. Traditional uses are increasingly being examined through molecular and clinical research. Conclusion: Adaptogenic herbs represent a promising class of natural agents with the potential to enhance stress tolerance, support physiological homeostasis, and exert neuroprotective and metabolic effects. Their multitarget mechanisms and reported clinical benefits support continued investigation of their use as complementary interventions for stress-related disorders. Larger, well-designed, standardized clinical trials are required to establish efficacy, optimal dosing, long-term safety, and clinically relevant herb–drug interactions.
Following publication of the article entitled “Comprehensive Review on Alzheimer’s Disease: Natural Therapeutics, Gaps, and Challenges” [1], certain phrases and expressions were identified that were unclear or inconsistent with established scientific terminologies. To ensure the accuracy and clarity of the published record, these expressions have been corrected using appropriate terminologies that more accurately convey the intended scientific meaning. These corrections are limited to the wordings and terminologies used in the affected passages, which do not alter the data, results, scientific interpretations, or conclusions of the article. The specific corrections are provided below: 1. INTRODUCTION, Paragraph 2 Original text: Even though the causes of Alzheimer's disease (AD) remain a mystery, various factors (such as overproduction and genetics, debilitated freedom, and NFT arrangement) have been connected to feeble plaque development, neurofibrillary tangle development, and far and wide neuronal passing [7]. Corrected text: Even though the causes of Alzheimer’s disease (AD) remain poorly understood, various factors, such as amyloid-β overproduction, genetic factors, impaired clearance, and neurofibrillary tangle (NFT) formation, have been linked to amyloid plaque formation, neurofibrillary tangle development, and widespread neuronal loss [7]. The original article has been updated accordingly. This Corrigendum is published to maintain transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/141326 The authors regret these errors and apologise for any inconvenience they may have caused.
Epilepsy continues to affect millions globally, and despite advances in treatment, many patients still struggle with drug-resistant forms of the disorder. Among the newer therapeutic options, racetam derivatives have garnered attention for their distinctive mechanism of action—modulating synaptic vesicle protein 2A (SV2A)—which distinguishes them from traditional antiepileptic drugs (AEDs). This review provides a closer examination of the structure–activity relationships (SAR) of racetam analogues, investigating how chemical modifications, such as aromatic substitution, halogenation, and alkyl chain extension, can significantly enhance key properties, including lipophilicity, blood–brain barrier penetration, metabolic stability, and receptor binding. By comparing well-known agents like piracetam and levetiracetam with newer, more refined molecules such as brivaracetam and seletracetam, we highlight the steady evolution in potency, selectivity, and pharmacokinetics. We also explore emerging strategies that aim to address current challenges in drug delivery and tolerability, ranging from stereochemical optimization to nanotechnology-based formulations and prodrug design. Recent findings from both preclinical and clinical studies (2021–2024) underscore the growing relevance of racetams in epilepsy care, highlighting the need for continued innovation in medicinal chemistry and translational research. Ultimately, racetam derivatives represent a compelling intersection of pharmaceutical design and neuropharmacology, offering a promising roadmap for the development of next-generation AEDs tailored to individual patient needs.
Introduction: Neurodegenerative diseases, especially Parkinson’s disease, have been linked with oxidative stress, mitochondrial malfunction, neuroinflammation, and dopamine metabolism impairment. On the other hand, C. album is a medicinal plant containing high concentrations of flavonoids, which provide neuroprotective potential by acting as antioxidants and MAO-B inhibitors. Methods: In this review, scientific data obtained by various approaches such as phytochemical screening, in vitro, in vivo, and computational analysis about significant flavonoids of C. album (e.g., quercetin, kaempferol, spinacetin) were collected. Characteristics, methods for identification, and biological activity were reviewed concerning their neuroprotective action. Results: Flavonoids present in C. album exhibited potent scavenging of free radicals, improved intrinsic defense systems, decreased lipid peroxidation, and maintenance of mitochondrial health. Quercetin and kaempferol exhibited remarkable inhibition of MAO-B activity, where as spinacetin analogs provided supplementary antioxidants and anti-inflammatory activities. Studies demonstrated lower levels of reactive oxygen species production, increased neuronal survival, decreased neuronal death, and favorable motor performance. Discussion: The multitarget effect of C. album flavonoids becomes especially important when considering degenerative nervous system disorders because a monotherapeutic approach cannot be effective in such cases. The simultaneous influence on oxidative stress, inflammation, apoptosis, and dopamine oxidation can help preserve dopaminergic neurons. Conclusion: The flavonoids from Chenopodium album have shown great potential as a neuroprotective agent. Still, further study is required before it can be used to treat any neurodegenerative condition in the clinical setting.